FDA Concludes Invokana, SGLT2 Inhibitors, Pose Serious Risks
Friday, December 4, the FDA announced that its concerns about SGLT2 inhibitors were confirmed. FDA Concludes Invokana, SGLT2 Inhibitors, Pose Serious Risks. In May 2015, the FDA announced it was investigating [...]